We established the preclinical safety and efficacy of live-attenuated Salmonella enterica Typhi strain ZH9 as a novel immunotherapy for NMIBC.Material and MethodsZH9 efficacy and mechanism of action (MOA) were tested in the murine orthotopic, syngeneic MB49 tumor model, compared to OncoTICE®BCG...Systemic priming further enhances immune responses and may therefore result in greater efficacy. This suggests that ZH9 immunotherapy may improve outcomes for patients with NMIBC, allowing less aggressive treatment and more reliable manufacturing method than the current SOC.
TICE BCG 50 mg was administered intravesically weekly x 6 weeks with maintenance therapy per the treating urologist’s discretion. Durvalumab in combination with intravesical BCG therapy or EBRT can be safely administered to NMIBC patients. Complete response rates in the treated BCG-unresponsive NMIBC population are promising with no unexpected adverse events observed. Longer-term follow up to assess the true frequency of durable responses at 12-months and beyond as well as validation of predictive biomarkers associated with durable responses is warranted.